WITH 23 MILLION  EU-funded IMPACT-MED project kicks off

Add new Admissions / Transfers

Integrated, multidisciplinary, and patient-centered. Collaboration between 26 partners from 13 European countries coordinated by theUniversità Campus Bio-Medico di RomaIMPACT-MED will support the Union's healthcare systems in the challenge of diseases that cause 4 million deaths every year and over €210 billion in costs in the cardiovascular field alone, with significant impacts on the quality of life of patients and their families. 

Factsheet: https://www.ihi.europa.eu/projects-results/project-factsheets/impact-med 

Website: https://impactmed-ihi.eu/ 

  • Funded by the European Commission and European industry associations: duration 60 months, April 2026 - March 2031, overall budget of 22,9 million euro, co-financed by Innovative Health Initiative Joint Undertaking in the IHI JU program under Horizon Europe and by European industrial associations of health technology producers: pharmaceuticals, biotechnology, medical devices, vaccines, and health information systems. 
  • European multidisciplinary consortium: IMPACT-MED brings together 26 partners from 13 European countries, including healthcare companies, universities, industries and patient organizations, coordinates of theUniversità Campus Bio-Medico di Roma and by Medtronic Ibérica (Spain). 
  • New model of integrated cardiometabolic care: the project will leverage the latest findings of theAI, wearables and innovative medical devices, redesigning integrated, multidisciplinary, and personalized care pathways to improve the prevention, diagnosis, treatment, monitoring, and long-term management of cardiometabolic diseases. 
  • Validation in real-world contexts: four clinical studies The pilot projects conducted at five European sites will test IMPACT-MED solutions in real-world healthcare settings, supporting their scalability, clinical effectiveness, and adoption across European healthcare systems. 

Rome, May 25, 2026 - Le cardiometabolic diseases including hypertension, diabetes, obesity and cardiovascular diseases such as ischemic heart disease and heart failure represent one of the main challenges for healthcare systems. They cause mortality, hospitalization, and long-term disability with an impact of 4 million deaths per year and over 210 billion euros in annual costs for cardiovascular diseases alone and significant impacts on the quality of life of patients and their families. 

To counteract these phenomena with a high social and economic impact and improve prevention, early diagnosis, continuity of care and personalization of treatments The European project IMPACT-MED started on 20 and 21 May in Rome with the aim of revolutionising the management of cardiometabolic diseases through a integrated, multidisciplinary, and patient-centered care model. 

The European project financed by Innovative Health Initiative Joint Undertaking (IHI JU) within Horizon Europe lasting 60 months (April 2026 – March 2031), can count on an overall budget of 22,9 million euro and is coordinated by Università Campus Bio-Medico di Roma e Medtronic IbéricaThe consortium brings together 26 partners from 13 European countriesRepresentatives from academia, clinical practice, industry, and patient organizations participated in the IMPACT-MED kick-off meeting, held at the Campus Bio-Medico University of Rome. 

IMPACT-MED will develop and validate an integrated cardiometabolic care model supported by a connected digital ecosystem, capable of combining: artificial intelligence, remote monitoring, clinical data and patient-generated data, advanced imaging, biomarkers, interoperable platforms. 

In particular, IMPACT-MED will test its solutions in real-world contexts through four clinical use cases: 

  • Artificial intelligence-based hypertension management. This pilot study, developed in Spain and led by Medtronic Ibérica together with the Hospital Clínico San Carlos through its research foundation, will evaluate how risk stratification using AI, remote blood pressure monitoring and digital tools to engage the patient can improve blood pressure control and promote earlier diagnosis of cardiovascular complications in high-risk patients. 
  • Remote monitoring of cardiovascular diseases. Developed in France by Medtronic France, AP-HP Hospitals and the ACTION cardiovascular research network, this study will examine how remote monitoring and predictive analytics tools can Strengthen outpatient follow-up, improve continuity of care, and help reduce unnecessary hospitalizations in patients with hypertension and previous myocardial infarctions. 
  • Patient support to improve self-management of type 1 diabetes. This use case, developed in the UK by Leeds Teaching Hospitals NHS Trust together with Medtronic International and DigiBete, will explore how remote monitoring and personalised digital education can improve therapeutic adherence, disease self-management and quality of care in children, adolescents and young adults with type 1 diabetes. 
  • Personalized care for type 2 diabetes and obesity. Developed in Denmark, this study combines the expertise of Perspectum and Siemens teams in Germany and India with the clinical and research capabilities of the North Denmark Region and Aalborg University. By integrating multi-organ phenotyping using advanced imaging techniques, patient-reported data on their experiences, and AI-based risk prediction tools, the study aims to: to support more personalized therapeutic decisions and improve patient clinical outcomes with type 2 diabetes and obesity. 

The four studies will allow us to evaluate clinical effectiveness, patient experience, economic sustainability and the possibility of integrating enabling technologies in European healthcare systems. 

Towards a more personalized and proactive medicine 

"IMPACT-MED was born from the belief that the future of cardiometabolic care lies in integration: not only of technologies, but also of disciplines, data and perspectives”, says Prof. Leandro Pecchia, Principal Investigator of the project at theUniversità Campus Bio-Medico di Roma. "We want to demonstrate that precision medicine and person-centered care are not separate goals, but the same goal.. " 

Secondo Jorge Posada, Head of Open Innovation and EU Project Management Office at Medtronic Ibérica, “Public-private collaboration is essential to transform technological innovation into a concrete and sustainable impact for patients and healthcare professionals." 

A project supported by the European Union 

IMPACT-MED is funded by Innovative Health Initiative Joint Undertaking (IHI JU) within the European programme Horizon Europe (Grant Agreement No. 101253530), with the support of the industry associations COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe, associations of manufacturers of healthcare information systems, pharmaceuticals, biotechnologies, medical devices and vaccines, respectively. 

Fact sheet: https://www.ihi.europa.eu/projects-results/project-factsheets/impact-med 

Website: https://impactmed-ihi.eu/